Several preclinical studies have already pinpointed interesting strategies for combination treatment involving buparlisib, for instance combination with a MEK inhibitor34, Bcl-2 inhibitor35 and CSF-1R inhibitor36 in GBM or a Smo antagonist in medulloblastoma37. Here, BCL2 is linked to glioblastoma.